G1 THERAPEUTICS (NASDAQ:GTHX) has been given an average broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.

Brokers have set a 12 month consensus price objective of $29.67 for the company, according to Zacks. Zacks has also assigned G1 THERAPEUTICS an industry rank of 154 out of 265 based on the ratings given to related companies.

Several research firms have commented on GTHX. Cowen and Company began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Needham & Company LLC began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 price target on the stock. Wedbush began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, J P Morgan Chase & Co began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 price target on the stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alps Advisors Inc. purchased a new position in shares of G1 THERAPEUTICS in the second quarter worth $444,000. Victory Capital Management Inc. purchased a new position in shares of G1 THERAPEUTICS in the second quarter worth $889,000. Goldman Sachs Group Inc. purchased a new position in shares of G1 THERAPEUTICS in the second quarter worth $1,144,000. Vanguard Group Inc. purchased a new position in shares of G1 THERAPEUTICS in the second quarter worth $1,291,000. Finally, Chartwell Investment Partners LLC purchased a new position in shares of G1 THERAPEUTICS in the second quarter worth $1,538,000. 35.10% of the stock is currently owned by institutional investors.

G1 THERAPEUTICS (NASDAQ:GTHX) opened at 26.51 on Monday. The firm has a 50-day moving average of $16.41 and a 200 day moving average of $16.78. The firm’s market capitalization is $749.84 million. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.54.

G1 THERAPEUTICS (NASDAQ:GTHX) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.48. Equities research analysts forecast that G1 THERAPEUTICS will post ($2.92) earnings per share for the current year.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/11/analysts-set-29-67-target-price-for-g1-therapeutics-gthx-2.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Get a free copy of the Zacks research report on G1 THERAPEUTICS (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.